Title : Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Pub. Date : 2008 Dec 10

PMID : 19001320






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Treatment with the BRAF inhibitor sorafenib restored sensitivity to panitumumab or cetuximab of CRC cells carrying the V600E allele. Sorafenib B-Raf proto-oncogene, serine/threonine kinase Homo sapiens